ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

SDEV vs INO // NET PROFIT MARGIN

Stablecoin Development Corporation (NYSE) VS. Inovio Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: SDEV 2 — INO 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SDEV VS. INO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC SDEV INO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -10.68% — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin ACTIVE — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) — -65.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 6.10% 0.00% +6.10 SDEV /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 44.5 27.1 +17.42 SDEV /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $79.0M $79.8M -$835.8K INO /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR SDEV REV INO REV SDEV GROSS % INO GROSS % SDEV FCF INO FCF
FY 2025 $0 $65.3K — — -$8.4M -$88.9M
FY 2024 $9.8M $217.8K 66.3% — -$7.5M -$104.6M
FY 2023 $0 $832.0K — — -$4.1M -$124.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SDEV // BETA —
INO // BETA —